Journal article
DNA vaccines: ready for prime time?
Nature reviews. Genetics, v 9(10), pp 776-788
Oct 2008
PMID: 18781156
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Since the discovery, over a decade and a half ago, that genetically engineered DNA can be delivered in vaccine form and elicit an immune response, there has been much progress in understanding the basic biology of this platform. A large amount of data has been generated in preclinical model systems, and more sustained cellular responses and more consistent antibody responses are being observed in the clinic. Four DNA vaccine products have recently been approved, all in the area of veterinary medicine. These results suggest a productive future for this technology as more optimized constructs, better trial designs and improved platforms are being brought into the clinic.
Metrics
Details
- Title
- DNA vaccines: ready for prime time?
- Creators
- Michele A Kutzler - Division of Infectious Diseases and HIV Medicine, The Department of Medicine, Drexel University College of Medicine, 245 North 15th Street, Philadelphia, Pennsylvania 19102, USADavid B Weiner - The Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA
- Publication Details
- Nature reviews. Genetics, v 9(10), pp 776-788
- Publisher
- Springer Nature
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Infectious Diseases (and HIV Medicine)
- Web of Science ID
- WOS:000259314000011
- Scopus ID
- 2-s2.0-52449104809
- Other Identifier
- 991014878009804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Genetics & Heredity